当前位置: X-MOL 学术Biochem. Genet. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
LncRNA HCG18 Promotes Osteosarcoma Cells Proliferation, Migration, and Invasion in by Regulating miR-34a/RUNX2 Pathway
Biochemical Genetics ( IF 2.4 ) Pub Date : 2022-11-19 , DOI: 10.1007/s10528-022-10294-5
Yi-Ping Chen 1 , Dong-Xin Zhang 2 , Qian Cao 3 , Chen-Kun He 2
Affiliation  

Osteosarcoma (OS) is a type of tumor with high malignant behaviors. Increasing investigates have confirmed that long non-coding RNA HLA complex group 18 (lncRNA HCG18) acted as a tumor-promoting factor in multiple tumors. Nevertheless, the underlying mechanism of HCG18 on OS remains largely unclear. HCG18, miR-34a, and runt-related transcription factor 2 (RUNX2) expressions were detected by quantitative real-time PCR (RT-qPCR) or western blotting assays, respectively. The underlying tumorigenic phenotypes were detected by MTT, wound healing, transwell invasion, western blotting assays. Molecular interactions were verified by dual-luciferase report assay. HCG18 and RUNX2 were notably enhanced, whereas miR-34a was decreased in OS tumor tissues and cell lines. Functional experiments uncovered that HCG18 silencing significantly inhibited the capabilities of proliferation, migration, and invasion, while overexpression of HCG18 play the opposite roles. Furthermore, HCG18 directly bound to miR-34a, and miR-34a was confirm to be a negative regulator of RUNX2. Interestingly, the anti-tumor effects of HCG18 silencing were attenuated by miR-34a inhibitor and RUNX2 overexpression. Taken together, the present study suggested that HCG18 promoted the malignant biological behaviors of OS through regulating the miR-34a/RUNX2 pathway, implying HCG18 might serve as a new target for OS treatment.



中文翻译:

LncRNA HCG18通过调节miR-34a/RUNX2通路促进骨肉瘤细胞增殖、迁移和侵袭

骨肉瘤(OS)是一种恶性程度较高的肿瘤。越来越多的研究证实,长链非编码RNA HLA复合体18 (lncRNA HCG18)在多种肿瘤中充当促癌因子。然而,HCG18 对 OS 的潜在机制仍不清楚。分别通过定量实时 PCR (RT-qPCR) 或蛋白质印迹法检测 HCG18、miR-34a 和 runt 相关转录因子 2 (RUNX2) 的表达。通过MTT、伤口愈合、Transwell侵袭、蛋白质印迹分析检测潜在的致瘤表型。通过双荧光素酶报告测定验证分子相互作用。在 OS 肿瘤组织和细胞系中,HCG18 和 RUNX2 显着增强,而 miR-34a 降低。功能实验发现,HCG18沉默显着抑制细胞增殖、迁移和侵袭能力,而HCG18过度表达则起到相反的作用。此外,HCG18直接与miR-34a结合,并且miR-34a被证实是RUNX2的负调节因子。有趣的是,HCG18 沉默的抗肿瘤作用因 miR-34a 抑制剂和 RUNX2 过表达而减弱。综上所述,本研究表明HCG18通过调节miR-34a/RUNX2通路促进OS的恶性生物学行为,这意味着HCG18可能作为OS治疗的新靶点。HCG18 沉默的抗肿瘤作用因 miR-34a 抑制剂和 RUNX2 过表达而减弱。综上所述,本研究表明HCG18通过调节miR-34a/RUNX2通路促进OS的恶性生物学行为,这意味着HCG18可能成为OS治疗的新靶点。HCG18 沉默的抗肿瘤作用因 miR-34a 抑制剂和 RUNX2 过表达而减弱。综上所述,本研究表明HCG18通过调节miR-34a/RUNX2通路促进OS的恶性生物学行为,这意味着HCG18可能作为OS治疗的新靶点。

更新日期:2022-11-19
down
wechat
bug